In cancer, particularly in hormone-dependent tumors such as breast and ovarian cancers, CYP19A1 is implicated in tumor progression through its role in estrogen biosynthesis, positioning it as a potential biomarker [47]. Here, CYP19A1 is linked to ovarian carcinoma.